TY - JOUR ID - TI - Changes in Coagulation Status in Patients with β-Thalassemia in Iraq: A Case-Control Study AU - Hussein Abdalzehra Wadaha AU - Hassan Dede Meshay AU - Mohammed Haseeb Khamees PY - 2022 VL - 19 IS - 2 SP - 157 EP - 161 JO - Medical Journal of Babylon مجلة بابل الطبية SN - 1812156X 23126760 AB - Background: The pathogenesis β-thalassemia is characterized by anemia resulting from reduced β-globin synthesis with low hemoglobinA (HbA) production and higher production of hemoglobin A2 (HbA2) and fetal hemoglobin (HbF). However, thromboembolicevents have been recently identified in patients with β-thalassemia due to hypercoagulable state. Objectives: The aim of this study wasto evaluate the levels of some coagulation markers in Iraqi patients with β-thalassemia major and β-thalassemia intermedia. Materialsand Methods: The study included three groups. The first group included patients with β-thalassemia major (n = 39), the second groupincluded patients with β-thalassemia intermedia (n = 11), and third group included 20 apparently healthy control subjects. Eachof prothrombin time (PT), activated partial thromboplastin time (APTT), antithrombin III (ATIII), and thrombin-antithrombinIII (TAT) complex were measured according to the standard protocols. Results: Both PT and APTT in β-thalassemia major andβ-thalassemia intermedia were higher than that of the control group with a highly significant difference (P = 0.002), whereas nosignificant differences were observed between patients with β-thalassemia major and β-thalassemia intermedia. Mean ATIII levelwas highest in the control group followed by β-thalassemia intermedia and then by β-thalassemia major groups (P < 0.001), whereasmean TAT complex was highest in thalassemia major group followed by β-thalassemia intermedia and then by control groups (P <0.001). Conclusions: Prolonged PT and APTT in patients with β-thalassemia together with the reduction in the level of anticoagulantfactor (ATII) suggest a role for liver impairment; however, the significantly higher TAT complex is suggestive of ongoing activation ofcoagulation cascade in patients with β-thalassemia.

ER -